lopinavir has been researched along with Inflammatory Response Syndrome, Systemic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Au, ICH; Chung, MSH; Cowling, BJ; Kwan, MYW; Kwok, ACY; Lau, EHY; Lau, KTK; Low, MCH; Lui, AYC; Wong, CKH; Xiong, X | 1 |
| Mamishi, S; Navaeian, A; Shabanian, R | 1 |
2 other study(ies) available for lopinavir and Inflammatory Response Syndrome, Systemic
| Article | Year |
|---|---|
Slower Recovery with Early Lopinavir/Ritonavir use in Pediatric COVID-19 Patients: A Retrospective Observational Study.
Topics: Child; COVID-19; COVID-19 Drug Treatment; HIV Infections; Humans; Lopinavir; Ritonavir; Systemic Inflammatory Response Syndrome | 2022 |
Acute aortic dissection in a patient with Williams syndrome infected by COVID-19.
Topics: Adolescent; Anti-Bacterial Agents; Antiviral Agents; Aortic Aneurysm; Aortic Dissection; Aortic Stenosis, Supravalvular; Aortitis; Azithromycin; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Enzyme Inhibitors; Fatal Outcome; Glucocorticoids; Humans; Hydroxychloroquine; Immunoglobulins, Intravenous; Immunologic Factors; Lopinavir; Male; Methylprednisolone; Oseltamivir; Recurrence; Ritonavir; SARS-CoV-2; Systemic Inflammatory Response Syndrome; Williams Syndrome | 2021 |